SFM
SPRY icon

Sphera Funds Management’s ARS Pharmaceuticals SPRY Stock Holding History

Sphera Funds Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-173,891
Closed -$5.37M – 147
2021
Q2 		$5.37M Buy
173,891
+6,092
+4% +$195K 0.36% 71
2021
Q1 		$7.32M Sell
167,799
-6,462
-4% -$306K 0.56% 50
2020
Q4 		$8.07M Buy
+174,261
New +$5.82M 0.72% 44

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sphera Funds Management's SPRY Position: Q3 2021 in Review

Sphera Funds Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2021, closing a stake of 173,891 shares — an estimated $5.37M sold.

Sphera Funds Management first reported a position in SPRY in Q4 2020 and held it in 3 quarters. The position peaked at $8.07M in Q4 2020. 74 funds tracked by Wall St. Rank hold SPRY as of Q3 2021.

  • Sphera Funds Management reported no remaining ARS Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sphera Funds Management sold 173,891 ARS Pharmaceuticals shares in Q3 2021, an estimated $5.37M.
  • Sphera Funds Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Sphera Funds Management's ARS Pharmaceuticals position peaked at $8.07M in Q4 2020.
  • 74 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2021.

Based on Sphera Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.